RxDoctor Payments Data

Olga Rao, MD

Family Medicine · Bronx, NYNPI 1790139426

Payments from drug & device makers

$462in general payments, 2019–2025

Across 8 payments — averaging $57.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$125
  • Gilead$125
  • AstraZeneca$85
  • Merck$64
  • Sunovion Pharmaceuticals Inc.$37
  • Lilly USA, LLC$15
  • plus $11 from 1 others

What the payments were for

  • Food & beverage$462100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$462 in reported general payments places this provider in the 50th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$126,728
Medicare patients
381
Services billed
1,790

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide52$80,087
MounjaroTirzepatide39$50,309
JardianceEmpagliflozin36$48,468
TrulicityDulaglutide26$43,426
EliquisApixaban37$38,764
JanuviaSitagliptin Phosphate24$34,455
XareltoRivaroxaban18$29,212
MyrbetriqMirabegron11$8,419
SynthroidLevothyroxine Sodium89$7,400
Rosuvastatin Calcium204$2,536
Atorvastatin Calcium327$2,378
Levothyroxine Sodium307$2,264
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$2,235
Telmisartan64$2,006
Metformin Hcl93$1,985

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$15$93,73565 claims
MerckJanuvia$64$34,45524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,321 family medicine providers in New York.

Other family medicine in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →